Cited by 248Psychedelics and Drug StudiesNeurotransmitter Receptor Influence on BehaviorForensic Toxicology and Drug Analysis

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Psychological and Physiological Effects of MDMA (“Ecstasy”) after Pretreatment with the 5-HT2 Antagonist Ketanserin in Healthy Humans

Liechti, M·2000·Neuropsychopharmacology

DOI 10.1016/s0893-133x(00)00126-3

Open this paper in CoChat — free account

Abstract

MDMA (3,4-methylenedioxymethamphetamine, "Ecstasy") mainly releases serotonin and dopamine. In animals, pretreatment with 5-HT(2) antagonists has been shown to attenuate neurochemical and behavioral effects of MDMA. In humans, the role of 5-HT(2) receptors in the action of MDMA has not been studied. We investigated the effect of pretreatment with the 5-HT(2A/C) antagonist ketanserin (50 mg p.o.) on subjective responses to MDMA (1.5 mg/kg p.o.) in 14 healthy volunteers using a double-blind placebo-controlled within-subject design. Subjective effects were rated by psychometric rating scales. Physiological effects measured were blood pressure, heart rate, and body temperature. Adverse effects were assessed during the sessions, and after one and three days. Ketanserin attenuated MDMA-induced perceptual changes, emotional excitation, and acute adverse responses but had little effect on MDMA-induced positive mood, well-being, extroversion, and short-term sequelae. Body temperature was lower under MDMA plus ketanserin compared to MDMA alone. The results suggest a contributing role for 5-HT(2) receptors in the action of MDMA in humans.

Integrity signals

Registry

Crossref · 10.1016/s0893-133x(00)00126-3

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

STAI manual for the State-trait anxiety inventory
Cd, S. (1970) · Medical Entomology and Zoology · Cited by 2,433
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptors
Leysen, J. E., Awouters, F. H. L., Kennis, L. E. J., Laduron, P. M., Vandenberk, J., & Janssen, P. A. J. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90747-5 · Cited by 843
Relationship between subjective effects of cocaine and dopamine transporter occupancy
Volkow, N. D., Wang, G., Fischman, M. W., Foltin, R. W., Fowler, J. S., Abumrad, N. N., Vitkun, S. A., Logan, J., Gatley, S. J., Pappas, N. R., et al. (1997) · Nature · doi:10.1038/386827a0 · Cited by 657
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & MCKENNEY, J. D. J. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 635
The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans
Dittrich, A. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979351 · Cited by 577
The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release.
Rudnick, G., & Wall, S. C. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1817 · Cited by 535
Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (“Ecstasy”) in MDMA-Naïve Healthy Volunteers
Vollenweider, F. X., Gamma, A., Liechti, M., & Huber, T. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00013-x · Cited by 448
Self-citation
Cardiovascular and Neuroendocrine Effects and Pharmacokinetics of 3,4-Methylenedioxymethamphetamine in Humans
Mas, M., Farré, M., de la Torre, R., Roset, P. N., Segura, J. O., & Camí, J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34877-3 · Cited by 362
Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens
Titeler, M., Lyon, R. A., & Glennon, R. A. (1988) · Psychopharmacology · doi:10.1007/bf00176847 · Cited by 343

Show all 34 references

Sorted by citations

The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
Green, A. R., Mechan, A. O., Elliott, J. M., O’Shea, E., & Colado, M. I. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.3 · Cited by 1,272
Pharmacological characterization of designer cathinonesin vitro
Simmler, L. D., Buser, T., Donzelli, M., Schramm, Y., Dieu, L., Huwyler, J., Chaboz, S., Hoener, M. C., & Liechti, M. E. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02145.x · Cited by 696
Self-citation
Toxicity of amphetamines: an update
Carvalho, M. C., Carmo, H., Costa, V. M., Capela, J. P., Pontes, H., Remião, F., Carvalho, F. D., & Bastos, M. D. L. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0815-5 · Cited by 449
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.11.015 · Cited by 427
Self-citation
Gender differences in the subjective effects of MDMA
Liechti, M. E., Gamma, A., & Vollenweider, F. X. (2001) · Psychopharmacology · doi:10.1007/s002130000648 · Cited by 360
Self-citation
The role of serotonin in drug use and addiction
Müller, C. P., & Homberg, J. R. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.04.007 · Cited by 345
A genetically encoded sensor for measuring serotonin dynamics
Wan, J., Peng, W., Li, X., Qian, T., Song, K., Zeng, J., Deng, F., Hao, S., Feng, J., Zhang, P., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00823-7 · Cited by 302
Molecular and Cellular Mechanisms of Ecstasy-Induced Neurotoxicity: An Overview
Capela, J. P., Carmo, H., Remião, F., Bastos, M. D. L., Meisel, A., & Carvalho, F. D. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8064-1 · Cited by 294
Drugs as instruments: A new framework for non-addictive psychoactive drug use
Müller, C. P., & Schumann, G. (2011) · Behavioral and Brain Sciences · doi:10.1017/s0140525x11000057 · Cited by 286
Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects
Holze, F., Vizeli, P., Müller, F., Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S., & Liechti, M. E. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0569-3 · Cited by 247
Self-citation
Is Ecstasy an “Empathogen”? Effects of +/- 3,4-Methylenedioxymethamphetamine on Prosocial Feelings and Identification of Emotional States in Others
Bedi, G., Hyman, D., & de Wit, H. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.003 · Cited by 247
Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies
Liechti, M. E., & Vollenweider, F. X. (2001) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.348 · Cited by 236
Self-citation
Effects of MDMA on sociability and neural response to social threat and social reward
Bedi, G., Phan, K. L., Angstadt, M., & de Wit, H. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1635-z · Cited by 206
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201
Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms
Lyles, J., & Cadet, J. L. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(03)00173-5 · Cited by 194
Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones
Rickli, A., Hoener, M. C., & Liechti, M. E. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.12.012 · Cited by 195
Self-citation
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: a mixed-methods systematic review.
Breeksema, J. J., Kuin, B. W., Kamphuis, J., van den Brink, W., Vermetten, E., & Schoevers, R. A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221116926 · Cited by 178
“, 2012), and acute, transient elevated vital signs, jaw clenching, perspiration, and lack of appetite with MDMA (Dumont and Verkes, 2006; Liechti et al., 2000; Vizeli and Liechti, 2017; Vizeli et al., 2019; Vollenweider et al., 1998).”
Background
The subjective effects of MDMA and mCPP in moderate MDMA users
Tancer, M. E., & Johanson, C. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(01)00146-6 · Cited by 179
The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity
Carhart-Harris, R. L., Murphy, K., Leech, R., Erritzøe, D., Wall, M. B., Ferguson, B., Williams, L. T. J., Roseman, L., Brugger, S. P., Meer, I. D., et al. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.12.015 · Cited by 187
Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics
Farré, M., de la Torre, R., Mathúna, B. Ó., Roset, P. N., Peiró, A. M., Torrens, M., Ortuño, J., Pujadas, M., & Camı́, J. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1789-7 · Cited by 165
Psychedelics and Other Psychoplastogens for Treating Mental Illness.
Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M., & Olson, D. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727117 · Cited by 166
The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals
Kamilar-Britt, P., & Bedi, G. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.08.016 · Cited by 163
Legal highs: staying on top of the flood of novel psychoactive substances
Baumeister, D., Tojo, L. M., & Tracy, D. K. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314559539 · Cited by 162
Human pharmacology of the methamphetamine stereoisomers
Mendelson, J. E., Uemura, N., Harris, D. E., NATH, R., FERNANDEZ, E., JACOBIII, P., Everhart, E. T., & JONES, R. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.06.013 · Cited by 158
The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA (“Ecstasy”) in Humans
Hysek, C. M., Simmler, L. D., Ineichen, M., Grouzmann, E., Hoener, M. C., Brenneisen, R., Huwyler, J., & Liechti, M. E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.78 · Cited by 152
Self-citation
Pivotal mental states
Brouwer, A., & Carhart-Harris, R. L. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120959637 · Cited by 174
A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers
Dumont, G. J. H., & Verkes, R. J. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106063271 · Cited by 149
Clinical Pharmacokinetics of Amfetamine and Related Substances
de la Torre, R., Farr, M., Navarro, M., Pacifici, R., Zuccaro, P., & Pichini, S. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443030-00002 · Cited by 154
5-HT receptors and reward-related behaviour: A review
Hayes, D. J., & Greenshaw, A. J. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.03.005 · Cited by 151
Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis
Yao, Y., Guo, D., Lu, T., Liu, F.-L., Huang, S., Diao, M.-Q., Li, S., Zhang, X.-J., Kosten, T. R., Shi, J., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115886 · Cited by 162
The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3, 4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers
Liechti, M. E., & Vollenweider, F. X. (2000) · Journal of Psychopharmacology · doi:10.1177/026988110001400313 · Cited by 144
Self-citation
Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons
Gudelsky, G. A., & Yamamoto, B. K. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.10.003 · Cited by 140
3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement
Fantegrossi, W. E., Ullrich, T., Rice, K. C., Woods, J. H., & Winger, G. D. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1021-6 · Cited by 132
How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy?
Kish, S. J. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00708-0 · Cited by 132
Brain mechanisms of hallucinogens and entactogens
Vollenweider, F. X. (2001) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2001.3.4/fxvollenweider · Cited by 129
Antagonism of serotonergic 5‐HT2A/2Creceptors: mutual improvement of sleep, cognition and mood?
Landolt, H., & Wehrle, R. (2009) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.06718.x · Cited by 136
Effects of Acute MDMA Intoxication on Mood and Impulsivity: Role of the 5-HT2 and 5-HT1 Receptors
van Wel, J. H. P., Kuypers, K. P. C., Theunissen, E. L., Bosker, W. M., Bakker, K., & Ramaekers, J. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040187 · Cited by 122
Cutaneous Vasoconstriction Contributes to Hyperthermia Induced by 3,4-Methylenedioxymethamphetamine (Ecstasy) in Conscious Rabbits
Pedersen, N. P., & Blessing, W. W. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-21-08648.2001 · Cited by 120
Pharmacological profile of novel psychoactive benzofurans
Rickli, A., Kopf, S., Hoener, M. C., & Liechti, M. E. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13128 · Cited by 114
Self-citation
The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans
Tancer, M., & Johanson, C.-E. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0576-z · Cited by 113
Serotonin and molecular neuroimaging in humans using PET
Saulin, A., Savli, M., & Lanzenberger, R. (2012) · Amino Acids · doi:10.1007/s00726-011-1078-9 · Cited by 113
A Comprehensive Review of MDMA and GHB: Two Common Club Drugs
Teter, C. J., & Guthrie, S. K. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.20.1486.34472 · Cited by 112
The effect of acutely administered MDMA on subjective and BOLD-fMRI responses to favourite and worst autobiographical memories
Carhart-Harris, R. L., Wall, M. B., Erritzoe, D., Kaelen, M., Ferguson, B., De Meer, I., Tanner, M., Bloomfield, M., Williams, T. M., Bolstridge, M., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001405 · Cited by 108
Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA)
Young, M. B., Norrholm, S. D., Khoury, L. M., Jovanovic, T., Rauch, S. A. M., Reiff, C. M., Dunlop, B. W., Rothbaum, B. O., & Howell, L. L. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4684-8 · Cited by 108
Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine
Dunlap, L. E., Andrews, A. M., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00155 · Cited by 106
Pharmacological profile of mephedrone analogs and related new psychoactive substances
Luethi, D., Kolaczynska, K. E., Docci, L., Krähenbühl, S., Hoener, M. C., & Liechti, M. E. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.026 · Cited by 106
Self-citation
LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making
Pokorny, T., Duerler, P., Seifritz, E., Vollenweider, F. X., & Preller, K. H. (2019) · Psychological Medicine · doi:10.1017/s0033291719002393 · Cited by 105
Effects of MDMA (Ecstasy) on Prepulse Inhibition and Habituation of Startle in Humans after Pretreatment with Citalopram, Haloperidol, or Ketanserin
Liechti, M. E. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00199-8 · Cited by 102
Self-citation
Acute Psychological and Neurophysiological Effects of MDMA in Humans
Vollenweider, F. X., Liechti, M. E., Gamma, A., Greer, G. R., & Geyer, M. A. (2002) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2002.10399951 · Cited by 89
Self-citation
Increased anxiety and "depressive" symptoms months after MDMA ("ecstasy") in rats: drug-induced hyperthermia does not predict long-term outcomes
McGregor, I. S., Gurtman, C. G., Morley, K. C., Clemens, K. J., Blokland, A., Li, K. M., Cornish, J. L., & Hunt, G. E. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1452-8 · Cited by 92
3,4-Methylenedioxymethamphetamine Self-Administration is Abolished in Serotonin Transporter Knockout Mice
Trigo, J. M., Renoir, T., Lanfumey, L., Hamon, M., Lesch, K., Robledo, P., & Maldonado, R. J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.11.005 · Cited by 91
The role of monoamines in the changes in body temperature induced by 3,4‐methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives
Docherty, J. R., & Green, A. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00722.x · Cited by 89
MDMA and temperature: A review of the thermal effects of ‘Ecstasy’ in humans
Parrott, A. C. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.08.012 · Cited by 87
Multiple 5-HT receptors are involved in the effects of acute MDMA treatment: studies on locomotor activity and responding for conditioned reinforcement
Fletcher, P. J., Korth, K. M., Robinson, S. K., & Baker, G. B. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1104-4 · Cited by 89
Ecstasy-induced cell death in cortical neuronal cultures is serotonin 2A-receptor-dependent and potentiated under hyperthermia
Capela, J. P., Ruscher, K., Lautenschlager, M., Freyer, D., Dirnagl, U., Gaio, R., Bastos, M. D. L., Meisel, A., & Carvalho, F. D. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.01.007 · Cited by 88
5-hydroxytryptamine2A receptors regulate sympathetic nerves constricting the cutaneous vascular bed in rabbits and rats
Blessing, W. W., & Seaman, B. W. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00810-2 · Cited by 88
In Vivo Imaging of Cerebral Serotonin Transporter and Serotonin2A Receptor Binding in 3,4-Methylenedioxymethamphetamine (MDMA or “Ecstasy”) and Hallucinogen Users
Erritzøe, D., Frøkjær, V. G., Holst, K. K., Christoffersen, M. V., Johansen, S. S., Svarer, C., Madsen, J., Rasmussen, P. M., Ramsøy, T. Z., Jernigan, T. L., et al. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.56 · Cited by 84
Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans
Hysek, C. M., Schmid, Y., Rickli, A., Simmler, L. D., Donzelli, M., Grouzmann, E., & Liechti, M. E. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01936.x · Cited by 86
Self-citation
Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting
Baggott, M. J., Coyle, J. R., Siegrist, J. D., Garrison, K. J., Galloway, G. P., & Mendelson, J. E. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115626348 · Cited by 79
Acute subjective effects in LSD- and MDMA-assisted psychotherapy
Schmid, Y., Gasser, P., Oehen, P., & Liechti, M. E. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959604 · Cited by 85
Self-citation
Decreased social behaviour following 3,4-methylenedioxymethamphetamine (MDMA) is accompanied by changes in 5-HT2A receptor responsivity
Bull, E., Hutson, P. H., & Fone, K. C. F. (2003) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.08.004 · Cited by 71
MDMA: Interactions with other psychoactive drugs
Mohamed, W. M. Y., Hamida, S. B., Cassel, J., de Vasconcelos, A. P., & Jones, B. C. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.06.032 · Cited by 77
Clozapine Reverses Hyperthermia and Sympathetically Mediated Cutaneous Vasoconstriction Induced by 3,4-Methylenedioxymethamphetamine (Ecstasy) in Rabbits and Rats
Blessing, W. W., Seaman, B. W., Pedersen, N. P., & Ootsuka, Y. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-15-06385.2003 · Cited by 72
Role of the serotonin 5-HT2A receptor in the hyperlocomotive and hyperthermic effects of (+)-3,4-methylenedioxymethamphetamine
Herin, D. V., Liu, S., Ullrich, T., Rice, K. C., & Cunningham, K. A. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2030-4 · Cited by 69
Behavioral effects of MDMA (‘ecstasy’) on adult zebrafish
Stewart, A., Riehl, R., Wong, K., Green, J. B. A., Cosgrove, J., Vollmer, K., Kyzar, E. J., Hart, P. C., Allain, A. V., Cachat, J., et al. (2011) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e328345f758 · Cited by 69
Effects of MDMA on body temperature in humans
Liechti, M. E. (2014) · Temperature · doi:10.4161/23328940.2014.955433 · Cited by 69
Self-citation
MDMA and MDMA-assisted therapy
Wolfgang, A. S., Fonzo, G. A., Gray, J. C., Krystal, J. H., Grzenda, A., Widge, A. S., Kraguljac, N. V., McDonald, W. M., Rodriguez, C. I., & Nemeroff, C. B. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230681 · Cited by 62
Effects of MDMA on Extracellular Dopamine and Serotonin Levels in Mice Lacking Dopamine and/or Serotonin Transporters
Hagino, Y., Takamatsu, Y., Yamamoto, H., Iwamura, T., Murphy, D. L., Uhl, G. R., Sora, I., & Ikeda, K. (2011) · Current Neuropharmacology · doi:10.2174/157015911795017254 · Cited by 60
Association between serotonin Cumulative Genetic Score and the Behavioral Approach System (BAS): Moderation by early life environment
Pearson, R., McGeary, J. E., & Beevers, C. G. (2014) · Personality and Individual Differences · doi:10.1016/j.paid.2014.06.041 · Cited by 59
Psychosis in Parkinson’s Disease
Wint, D. P., Okun, M. S., & Fernandez, H. H. (2004) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988704267457 · Cited by 60
α1-Adrenergic Receptors Contribute to the Acute Effects of 3,4-Methylenedioxymethamphetamine in Humans
Hysek, C. M., Fink, A. E., Simmler, L. D., Donzelli, M., Grouzmann, E., & Liechti, M. E. (2013) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3182979d32 · Cited by 60
Self-citation
Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances
Simmler, L. D., & Liechti, M. E. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_113 · Cited by 58
Self-citation
MDMA (“ecstasy”) abuse as an example of dopamine neuroplasticity
Schenk, S. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.12.010 · Cited by 43
Blockade of 5-HT2 Receptor Selectively Prevents MDMA-Induced Verbal Memory Impairment
van Wel, J. H. P., Kuypers, K. P. C., Theunissen, E. L., Bosker, W. M., Bakker, K., & Ramaekers, J. G. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.80 · Cited by 53
Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA
Hasler, F., Studerus, E., Lindner, K., Ludewig, S., & Vollenweider, F. X. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094650 · Cited by 54
Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug–drug interactions
Rietjens, S. J., Hondebrink, L., Westerink, R. H. S., & Meulenbelt, J. (2012) · Critical Reviews in Toxicology · doi:10.3109/10408444.2012.725029 · Cited by 53
Effects of a -blocker on the cardiovascular response to MDMA (Ecstasy)
Hysek, C. M., Vollenweider, F. X., & Liechti, M. E. (2010) · Emergency Medicine Journal · doi:10.1136/emj.2009.079905 · Cited by 51
Self-citation
Separating the agony from ecstasy: R(–)-3,4-methylenedioxymethamphetamine has prosocial and therapeutic-like effects without signs of neurotoxicity in mice
Curry, D. W., Young, M. B., Tran, A., Daoud, G. E., & Howell, L. L. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.003 · Cited by 50
Long-term behavioral consequences of prenatal MDMA exposure
Thompson, V. B., Heiman, J. U., Chambers, J. B., Benoit, S. C., Buesing, W. R., Norman, M. K., Norman, A. B., & Lipton, J. W. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.12.013 · Cited by 49
Methylenedioxymethamphetamine (MDMA): Serotonergic and dopaminergic mechanisms related to its use and misuse
Schenk, S., & Highgate, Q. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15348 · Cited by 48
Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart
Peiró, A. M., Farré, M., Roset, P. N., Carbó, M., Pujadas, M., Torrens, M., Camı́, J., & de la Torre, R. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2894-7 · Cited by 48
Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models
Agnorelli, C., Spriggs, M. J., Godfrey, K., Sawicka, G., Bohl, B., Douglass, H. M., Fagiolini, A. M., Parastoo, H., Carhart-Harris, R. L., Nutt, D. J., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106132 · Cited by 65
Hyperthermia induced by 3,4-methylenedioxymethamphetamine in unrestrained rhesus monkeys
Taffe, M. A., Lay, C. C., Huben, S. N. V., Davis, S. A., Crean, R. D., & Katner, S. N. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.09.013 · Cited by 47
Altered Insula Connectivity under MDMA
Walpola, I. C., Nest, T., Roseman, L., Erritzøe, D., Feilding, A., Nutt, D., & Carhart-Harris, R. L. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.35 · Cited by 47
The Future of Technology in Positive Psychology: Methodological Advances in the Science of Well-Being
Yaden, D. B., Eichstaedt, J. C., & Medaglia, J. D. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.00962 · Cited by 44
Selective verbal and spatial memory impairment after 5-HT 1A and 5-HT 2A receptor blockade in healthy volunteers pre-treated with an SSRI
Wingen, M., Kuypers, K. P. C., & Ramaekers, J. G. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106072506 · Cited by 44
The sub-acute effects of recreational ecstasy (MDMA) use: a controlled study in humans
Huxster, J. K., Pirona, A., & Morgan, M. J. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060513 · Cited by 43
Proposed Consensus Statement on Defining Psychedelic Drugs
Nichols, D. E., Nichols, C. D., & Hendricks, P. S. (2022) · Psychedelic Medicine · doi:10.1089/psymed.2022.0008 · Cited by 42
The role of 5-HT1a and 5-HT2a receptors in attention and motor control: a mechanistic study in healthy volunteers
Wingen, M., Kuypers, K. P. C., & Ramaekers, J. G. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0614-x · Cited by 44
Effects of the new psychoactive substances diclofensine, diphenidine, and methoxphenidine on monoaminergic systems
Luethi, D., Hoener, M. C., & Liechti, M. E. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.12.012 · Cited by 41
Self-citation
(±)-MDMA and its enantiomers: potential therapeutic advantages of R(−)-MDMA
Pitts, E. G., Curry, D. W., Hampshire, K. N., Young, M. B., & Howell, L. L. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4812-5 · Cited by 41
Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy
Oeri, H. E. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120920420 · Cited by 43
Characterizing Thalamocortical (Dys)connectivity Following D-Amphetamine, LSD, and MDMA Administration
Avram, M., Müller, F., Rogg, H. V., Korda, A. I., Andreou, C., Holze, F., Vizeli, P., Ley, L., Liechti, M. E., & Borgwardt, S. (2022) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2022.04.003 · Cited by 47
Self-citation
Mephedrone and MDMA: A comparative review
Mead, J., & Parrott, A. (2020) · Brain Research · doi:10.1016/j.brainres.2020.146740 · Cited by 39
Involvement of 5-HT2A receptors in MDMA reinforcement and cue-induced reinstatement of MDMA-seeking behaviour
Orejarena, M. J., Lanfumey, L., Maldonado, R. J., & Robledo, P. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001215 · Cited by 38
Effects of (±)3,4-methylenedioxymethamphetamine, (±)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques
Crean, R. D., Davis, S. A., Huben, S. N. V., Lay, C. C., Katner, S. N., & Taffe, M. A. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.06.033 · Cited by 39
Can MDMA Play a Role in the Treatment of Substance Abuse?
Jerome, L., Schuster, S., & Yazar‐Klosinski, B. (2013) · Current Drug Abuse Reviews · doi:10.2174/18744737112059990005 · Cited by 39
What is the evidence that Ecstasy (MDMA) can cause Parkinson's disease?
Kish, S. J. (2003) · Movement Disorders · doi:10.1002/mds.10643 · Cited by 37
Psychedelics for treatment resistant depression: are they game changers?
Kalfas, M., Taylor, R. H., Tsapekos, D., & Young, A. H. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2281582 · Cited by 37
MDMA interactions with pharmaceuticals and drugs of abuse
Papaseit, E., Pérez‐Mañá, C., Torrens, M., Farré, A., Poyatos, L., Hladun, O., Sanvisens, A., Muga, R., & Farré, M. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1749262 · Cited by 37

Authors: Liechti, M.
Affiliations: Psychiatrische Universitätsklinik Zürich (CH)
Corresponding author: Liechti, M
ORCID: Liechti, M
Venue: Neuropsychopharmacology
Publisher: Springer Science and Business Media LLC
Published: 2000-10
Volume: 23
Issue: 4
Pages: 396-404
ISSN: 0893-133X (ISSN-L)
DOI: 10.1016/s0893-133x(00)00126-3
OpenAlex: W2137229007
Cited by: 245
References: 34
Citations by year: 2026: 7 · 2025: 6 · 2024: 15 · 2023: 9 · 2022: 10 · 2021: 10 · 2020: 7 · 2019: 5 · 2018: 12 · 2017: 14 · 2016: 8 · 2015: 9 · 2014: 13 · 2013: 5 · 2012: 13
FWCI: 10.33
Type: journal article
Language: en
Open access: closed
Locations: Neuropsychopharmacology (publishedVersion)
PubMed (publishedVersion)
Funders: Heffter Research Institute
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
Keywords: MDMA, ecstasy, ketanserin, 5-HT2 receptor antagonism, serotonin, subjective effects, perceptual change, emotional arousal, body temperature, blood pressure, heart rate, adverse effects, drug interactions
MeSH terms: Adult, Affect, Analysis of Variance, Blood Pressure, Body Temperature, Double-Blind Method, Female, Hallucinations, Hallucinogens, Heart Rate, Humans, Ketanserin, Male, Perception, Psychometrics, Receptors, Serotonin, Serotonin Antagonists, Serotonin Agents, Statistics, Nonparametric, N-Methyl-3,4-methylenedioxyamphetamine, Receptor, Serotonin, 5-HT2A, Receptor, Serotonin, 5-HT2C

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Psychological and Physiological Effects of MDMA (“Ecstasy”) after Pretreatment with the 5-HT2 Antagonist Ketanserin in Healthy Humans

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks